Versartis Inc. (NASDAQ:VSAR) traded up 5.6% during trading on Friday . The company traded as high as $10.69 and last traded at $10.60, with a volume of 135,342 shares. The stock had previously closed at $10.04.

Several research analysts recently weighed in on the company. Morgan Stanley reiterated a “hold” rating on shares of Versartis in a research report on Saturday, April 30th. Zacks Investment Research cut Versartis from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Canaccord Genuity reiterated a “buy” rating on shares of Versartis in a research report on Tuesday, May 10th. Finally, Northland Securities assumed coverage on Versartis in a research report on Thursday, April 7th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $17.20.

The company’s 50 day moving average price is $10.33 and its 200-day moving average price is $9.38. The firm’s market capitalization is $311.94 million.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.